Regenxbio RGNX Novartis Royalties — Unbilled Receivables Current
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Regenxbio in its filing.
Tagged under the XBRL concept us-gaap:UnbilledReceivablesCurrent.
The official record: Regenxbio’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →
Ask your AI about Regenxbio's novartis royalties — unbilled receivables current.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Regenxbio's novartis royalties — unbilled receivables current?
- Regenxbio (RGNX) reported novartis royalties — unbilled receivables current of $5.05M in Q1 2026.
- What does novartis royalties — unbilled receivables current mean?
- This metric represents the current portion of accrued royalty revenue earned from licensing agreements with Novartis that has been recognized in the financial statements but not yet invoiced to the partner. It reflects the timing difference between the recognition of revenue based on the partner's product sales and the contractual billing cycle. Monitoring this balance provides insight into the cash conversion cycle and the reliability of royalty-based revenue streams from strategic licensing partnerships.